Cargando…
Polyphenols for the Treatment of Ischemic Stroke: New Applications and Insights
Ischemic stroke (IS) is a leading cause of death and disability worldwide. Currently, the main therapeutic strategy involves the use of intravenous thrombolysis to restore cerebral blood flow to prevent the transition of the penumbra to the infarct core. However, due to various limitations and compl...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268254/ https://www.ncbi.nlm.nih.gov/pubmed/35807426 http://dx.doi.org/10.3390/molecules27134181 |
_version_ | 1784743931685109760 |
---|---|
author | Liu, Shuhan Lin, Feng Wang, Jian Pan, Xiaoqiang Sun, Liguang Wu, Wei |
author_facet | Liu, Shuhan Lin, Feng Wang, Jian Pan, Xiaoqiang Sun, Liguang Wu, Wei |
author_sort | Liu, Shuhan |
collection | PubMed |
description | Ischemic stroke (IS) is a leading cause of death and disability worldwide. Currently, the main therapeutic strategy involves the use of intravenous thrombolysis to restore cerebral blood flow to prevent the transition of the penumbra to the infarct core. However, due to various limitations and complications, including the narrow time window in which this approach is effective, less than 10% of patients benefit from such therapy. Thus, there is an urgent need for alternative therapeutic strategies, with neuroprotection against the ischemic cascade response after IS being one of the most promising options. In the past few decades, polyphenolic compounds have shown great potential in animal models of IS because of their high biocompatibility and ability to target multiple ischemic cascade signaling pathways, although low bioavailability is an issue that limits the applications of several polyphenols. Here, we review the pathophysiological changes following cerebral ischemia and summarize the research progress regarding the applications of polyphenolic compounds in the treatment of IS over the past 5 years. Furthermore, we discuss several potential strategies for improving the bioavailability of polyphenolic compounds as well as some essential issues that remain to be addressed for the translation of the related therapies to the clinic. |
format | Online Article Text |
id | pubmed-9268254 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92682542022-07-09 Polyphenols for the Treatment of Ischemic Stroke: New Applications and Insights Liu, Shuhan Lin, Feng Wang, Jian Pan, Xiaoqiang Sun, Liguang Wu, Wei Molecules Review Ischemic stroke (IS) is a leading cause of death and disability worldwide. Currently, the main therapeutic strategy involves the use of intravenous thrombolysis to restore cerebral blood flow to prevent the transition of the penumbra to the infarct core. However, due to various limitations and complications, including the narrow time window in which this approach is effective, less than 10% of patients benefit from such therapy. Thus, there is an urgent need for alternative therapeutic strategies, with neuroprotection against the ischemic cascade response after IS being one of the most promising options. In the past few decades, polyphenolic compounds have shown great potential in animal models of IS because of their high biocompatibility and ability to target multiple ischemic cascade signaling pathways, although low bioavailability is an issue that limits the applications of several polyphenols. Here, we review the pathophysiological changes following cerebral ischemia and summarize the research progress regarding the applications of polyphenolic compounds in the treatment of IS over the past 5 years. Furthermore, we discuss several potential strategies for improving the bioavailability of polyphenolic compounds as well as some essential issues that remain to be addressed for the translation of the related therapies to the clinic. MDPI 2022-06-29 /pmc/articles/PMC9268254/ /pubmed/35807426 http://dx.doi.org/10.3390/molecules27134181 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Liu, Shuhan Lin, Feng Wang, Jian Pan, Xiaoqiang Sun, Liguang Wu, Wei Polyphenols for the Treatment of Ischemic Stroke: New Applications and Insights |
title | Polyphenols for the Treatment of Ischemic Stroke: New Applications and Insights |
title_full | Polyphenols for the Treatment of Ischemic Stroke: New Applications and Insights |
title_fullStr | Polyphenols for the Treatment of Ischemic Stroke: New Applications and Insights |
title_full_unstemmed | Polyphenols for the Treatment of Ischemic Stroke: New Applications and Insights |
title_short | Polyphenols for the Treatment of Ischemic Stroke: New Applications and Insights |
title_sort | polyphenols for the treatment of ischemic stroke: new applications and insights |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268254/ https://www.ncbi.nlm.nih.gov/pubmed/35807426 http://dx.doi.org/10.3390/molecules27134181 |
work_keys_str_mv | AT liushuhan polyphenolsforthetreatmentofischemicstrokenewapplicationsandinsights AT linfeng polyphenolsforthetreatmentofischemicstrokenewapplicationsandinsights AT wangjian polyphenolsforthetreatmentofischemicstrokenewapplicationsandinsights AT panxiaoqiang polyphenolsforthetreatmentofischemicstrokenewapplicationsandinsights AT sunliguang polyphenolsforthetreatmentofischemicstrokenewapplicationsandinsights AT wuwei polyphenolsforthetreatmentofischemicstrokenewapplicationsandinsights |